230 related articles for article (PubMed ID: 26183292)
1. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinase inhibition as a cancer therapeutic strategy.
D'Arcy P; Wang X; Linder S
Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
4. Proteasome deubiquitinases as novel targets for cancer therapy.
D'Arcy P; Linder S
Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
[TBL] [Abstract][Full Text] [Related]
5. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
6. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: translational potential of deubiquitinases as drug targets.
D'Arcy P; Linder S
Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788
[TBL] [Abstract][Full Text] [Related]
8. Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.
Chen X; Yang Q; Xiao L; Tang D; Dou QP; Liu J
Cancer Metastasis Rev; 2017 Dec; 36(4):655-668. PubMed ID: 29039082
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.
Chen X; Yang Q; Chen J; Zhang P; Huang Q; Zhang X; Yang L; Xu D; Zhao C; Wang X; Liu J
Cell Physiol Biochem; 2018; 49(2):780-797. PubMed ID: 30165348
[TBL] [Abstract][Full Text] [Related]
10. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Zhao C; Chen X; Yang C; Zang D; Lan X; Liao S; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; Dou QP; Wang X; Liu J
Oncotarget; 2017 Feb; 8(8):13942-13956. PubMed ID: 28086217
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S
Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145
[TBL] [Abstract][Full Text] [Related]
12. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
Pal A; Young MA; Donato NJ
Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
[TBL] [Abstract][Full Text] [Related]
13. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X
Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
16. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
17. The bad seed gardener: Deubiquitinases in the cancer stem-cell signaling network and therapeutic resistance.
Qiu GZ; Sun W; Jin MZ; Lin J; Lu PG; Jin WL
Pharmacol Ther; 2017 Apr; 172():127-138. PubMed ID: 27919796
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
19. Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells.
Ahmed ZSO; Li X; Li F; Cheaito HA; Patel K; Mosallam EM; Elbargeesy GAEH; Dou QP
J Cell Biochem; 2018 Nov; 119(11):9006-9016. PubMed ID: 30015387
[TBL] [Abstract][Full Text] [Related]
20. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
